What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Khavinson immune / endocrine short-peptide bioregulator
Overview
Crystagen is a synthetic short-chain peptide bioregulator developed by Prof. Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology. Its active substance is the "AC-6 peptide complex," whose core sequence is glutamic acid-aspartic acid-proline (Glu-Asp-Pro, abbreviated EDP, H-Glu-Asp-Pro-OH). It was originally isolated as one of the principal active short peptides within Thymalin, a bovine-thymus-extract preparation approved in Russia in 1982, and is documented in US Patent 8057810B2 ("Peptide substance revealing an immunogeroprotective effect"). This independent re-verification (third pass, with the full patent text re-fetched directly from Google Patents and checked word-for-word) confirmed the sequence H-Glu-Asp-Pro-OH, molecular formula C14H21N3O8, and molecular weight 359.33 — but the patent text itself never uses the name "Crystagen" or "AC-6." The only route to that trade-name linkage is an indirect one via the patent-listing page on Khavinson's official site (khavinson.info): this pass fetched that page directly and found its glutamyl-aspartyl-proline entry is actually a related national-phase patent, Israeli patent IL 194499 (same inventors, same underlying invention as US8057810B2, filed in a different country) — and that page likewise does not attach the "Crystagen" or "AC-6" brand name to the entry. This link should be read as indirect (via a sister patent plus an official-site association) rather than a direct textual confirmation, stated here explicitly for transparency. The peptide belongs to Khavinson's synthetic "Cytogen" series (paired with the natural-extract "Cytomax" series, e.g., Thymalin/Vladonix), and the original product is sold in Russia and some overseas channels (CosmicNootropic, antiaging-systems.com, ipept.com) as an oral capsule or sublingual drop under the brand Crystagen®, positioned as a synthetic counterpart to a natural thymic extract. It is currently sold through RUO channels as synthetic peptide powder/pre-mixed solution, for laboratory research use only — not for human or animal clinical use. Importantly: sequence labeling confusion in the RUO market is significant. Beyond the previously identified mislabels — Thr-Lys-Asp (TKD, actually Thymogen's sequence) and Lys-Glu-Asp (KED, actually Vesugen's sequence) — this pass again independently confirmed two further conflicting labels in circulation: peptidedistro.com lists Pro-Gln-Asn (proline-glutamine-asparagine), and antiaging-systems.com lists a composition of "glycine, glutamic acid, and aspartic acid" (which also doesn't fully match yet another independent source, peptide-products.com, describing AC-6 as composed of "proline, glutamic acid, aspartic acid" — market labeling is inconsistent across many variants). Cross-checked directly against the full text of US Patent 8057810B2, Glu-Asp-Pro (EDP) should be treated as the correct sequence; all other labels found are market mislabeling, and buyers should require batch-specific COA confirmation (ESI-MS + HPLC) from suppliers. Vialdyne releases Crystagen as a lyophilized tripeptide (linear) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Copper peptides require chelator-free water and EDTA-free buffers in downstream formulation work.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Crystagen, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
These thymic-immune materials are not interchangeable: Thymulin is a defined nine-residue zinc-binding peptide with a registered CAS, Thymalin is a multi-peptide bovine-thymus extract, and Crystagen is a defined Khavinson-class short peptide. The released COA must state which compositional class the shipped material represents, single defined peptide versus complex extract, plus the analytical method used to confirm it. For Crystagen specifically, require a sequence assignment and an HPLC purity result against its acceptance limit. Confirm the stated class matches your order at receipt, since class mismatch here cannot be caught by inspection alone.
Log the lot number, net-peptide assay basis, salt form, water content, and re-test date, then verify identity with an orthogonal check pairing an HPLC purity determination with mass confirmation against the COA. Store the lyophilizate at -20 degrees Celsius protected from light and track the assigned re-test interval so shelf-life is auditable. Reconstitute in isotonic saline at near-neutral pH and calculate working concentration from the net-peptide figure rather than gross fill. Aliquot into single-use volumes immediately and hold frozen, since freeze-thaw cycling is the main in-lab degradation route for short peptides.
